ADHD Meds Up Cardiac Event Risk in Long-QT Syndrome

This article originally appeared here.
Share this content:
ADHD Meds Up Cardiac Event Risk in Long-QT Syndrome
ADHD Meds Up Cardiac Event Risk in Long-QT Syndrome

TUESDAY, Oct. 27, 2015 (HealthDay News) -- Patients with long-QT syndrome (LQTS) treated with attention deficit/hyperactivity disorder (ADHD) medications have an increased risk for cardiac events, according to a study published in the October issue of the Journal of Cardiovascular Electrophysiology.

Claire Zhang, M.D., from the University of Rochester in New York, and colleagues compared 48 LQTS patients identified in the Rochester-based LQTS Registry (open enrollment between 1979 and 2003) treated with stimulant or nonstimulant ADHD medications to 96 age-, gender-, and QTc-duration-matched LQTS controls not exposed to ADHD medications.

The researchers found that over a mean follow-up of 7.9 years after initiation of ADHD medication (mean age, 10.7 years), there was a 62 percent cumulative probability of cardiac events in the ADHD treatment group versus 28 percent in the matched LQTS control group. Use of ADHD medication was associated in a time-dependent fashion with an increased risk for cardiac events (hazard ratio [HR], 3.07) after adjustment for time-dependent beta-blocker use and prior cardiac events. Time-dependent ADHD medication was associated with an increased risk in male LQTS patients (HR, 6.8) in subgroup gender analyses.

"The findings highlight the importance of heightened surveillance for LQTS patients on ADHD medications," conclude the authors.

GeneDx provided financial support to the LQTS Registry.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »